These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3346993)

  • 1. Diagnostic and therapeutic technology assessment. BCG immunotherapy in bladder cancer: a reassessment.
    JAMA; 1988 Apr; 259(14):2153-5. PubMed ID: 3346993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and therapeutic technology assessment. Bacillus Calmette-Guerin immunotherapy in bladder cancer.
    JAMA; 1987 Mar; 257(9):1238-40. PubMed ID: 3806925
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
    Brosman SA
    Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 6. BCG in bladder cancer--a warning.
    Nicol D
    Aust N Z J Med; 1995 Aug; 25(4):275-7. PubMed ID: 8540864
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
    Barreto L; Csizer Z; Sparkes JD
    Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.
    Lamm DL
    Oncology (Williston Park); 1995 Oct; 9(10):947-52, 955, discussion 955-65. PubMed ID: 8573479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
    Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
    Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCG for bladder cancer.
    Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intravesical BCG as a treatment for superficial and in situ transitional cell carcinoma of the bladder].
    Schmidt AC; de Kock ML; de Klerk DP
    S Afr Med J; 1990 Apr; 77(7):354-7. PubMed ID: 2321105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant immunotherapy in superficial bladder cancer.
    Morales A
    Natl Cancer Inst Monogr; 1978 Dec; (49):315-9. PubMed ID: 748787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arthritis and iritis after BCG therapy for bladder cancer.
    Price GE
    J Rheumatol; 1994 Mar; 21(3):564-5. PubMed ID: 8006904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 15. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG].
    Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V
    An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up of the effect of BCG vaccine treatment in bladder tumour patients.
    Kulcsár G; Nász I; Tenke P; Csata S
    Acta Microbiol Hung; 1993; 40(2):151-7. PubMed ID: 8184669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
    Jakse G; Hall R; Bono A; Höltl W; Carpentier P; de Pauw M; Sylvester R
    Prog Clin Biol Res; 1992; 378():69-74. PubMed ID: 1301588
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy of superficial bladder cancer.
    Nseyo UO; Lamm DL
    Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.